ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2025
Impact of Hyperglycemia on Tear Film and Meibomian Gland Dysfunction: A Cross-Sectional Study.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The Interaction of Diabetes Duration and Tear Film Osmolarity in the Estimation of Tear Film Instability: A Cross-Sectional Study of 60 Patients with Type 2 Diabetes.Journal of clinical medicine · 2026Article
- Tear Film Alterations in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.Diagnostics (Basel, Switzerland) · 2025Review
- Beyond the Surface: Revealing the Concealed Effects of Hyperglycemia on Ocular Surface Homeostasis and Dry Eye Disease.Medicina (Kaunas, Lithuania) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Elevated blood glucose levels may disrupt tear film and meibomian gland function, contributing to dry eye disease (DED) and meibomian gland dysfunction (MGD). This study aimed to explore the relationship between hyperglycemia and DED parameters. Methods: A cross-sectional study at Chifeng Chaoju Eye Hospital (June-August 2024) included 56 participants with DED symptoms. Tear meniscus height (TMH), non-invasive tear film breakup time (FNIBUT, ANIBUT), bulbar redness, and meibomian gland atrophy (U-LAMG, L-LAMG) were assessed using a non-invasive ocular surface analyzer. Fasting blood glucose levels stratified patients into high (≥7 mmol/l) and normal (<7 mmol/l) groups, and their association with DED parameters was analyzed. Results: Among 56 patients (mean age 52.5 ± 18.0 years), those with elevated glucose levels (n=28) had more severe DED symptoms (OSDI, p = 0.046), lower TMH, FNIBUT, ANIBUT, and higher bulbar redness scores (all p < 0.05). In contrast, lower glucose levels were associated with greater U-LAMG and L-LAMG atrophy (p < 0.05). Glucose positively correlated with intraocular pressure (IOP), redness, U-LAMG, and L-LAMG but negatively correlated with TMH, FNIBUT, and ANIBUT (all p < 0.05). Conclusion: Hyperglycemia is linked to impaired tear film stability, meibomian gland function, and DED symptoms. Ocular surface disorders in individuals with diabetes may be prevented by effective glycemic control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.